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a b s t r a c t
Background: Distinguishing bacterial and viral respiratory infections is challenging. Novel diagnostics
based on differential host gene expression patterns are promising but have not been translated to a clinical platform nor extensively tested. Here, we validate a microarray-derived host response signature and
explore performance in microbiology-negative and coinfection cases.
Methods: Subjects with acute respiratory illness were enrolled in participating emergency departments.
Reference standard was an adjudicated diagnosis of bacterial infection, viral infection, both, or neither. An
87-transcript signature for distinguishing bacterial, viral, and noninfectious illness was measured from
peripheral blood using RT-PCR. Performance characteristics were evaluated in subjects with conﬁrmed
bacterial, viral, or noninfectious illness. Subjects with bacterial-viral coinfection and microbiologicallynegative suspected bacterial infection were also evaluated. Performance was compared to procalcitonin.
Findings: 151 subjects with microbiologically conﬁrmed, single-etiology illness were tested, yielding AUROCs 0•85–0•89 for bacterial, viral, and noninfectious illness. Accuracy was similar to procalcitonin (88%
vs 83%, p = 0•23) for bacterial vs. non-bacterial infection. Whereas procalcitonin cannot distinguish viral
from non-infectious illness, the RT-PCR test had 81% accuracy in making this determination. Bacterialviral coinfection was subdivided. Among 19 subjects with bacterial superinfection, the RT-PCR test identiﬁed 95% as bacterial, compared to 68% with procalcitonin (p = 0•13). Among 12 subjects with bacterial
infection superimposed on chronic viral infection, the RT-PCR test identiﬁed 83% as bacterial, identical to
procalcitonin. 39 subjects had suspected bacterial infection; the RT-PCR test identiﬁed bacterial infection
more frequently than procalcitonin (82% vs 64%, p = 0•02).
Interpretation: The RT-PCR test offered similar diagnostic performance to procalcitonin in some subgroups
but offered better discrimination in others such as viral vs. non-infectious illness and bacterial/viral coinfection. Gene expression-based tests could impact decision-making for acute respiratory illness as well as
a growing number of other infectious and non-infectious diseases.
Published by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license.
(http://creativecommons.org/licenses/by-nc-nd/4.0/)
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2352-3964/Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license. (http://creativecommons.org/licenses/by-nc-nd/4.0/)
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Research in context
Evidence before this study: A number of studies have turned
to the human host response as an alternative diagnostic strategy
given the limitations of traditional pathogen-based testing. This
growing body of work includes broad classiﬁers for identifying the
etiology of respiratory infection, pediatric febrile illness, and sepsis, as well as pathogen-speciﬁc classiﬁers for tuberculosis, Lyme
disease, and Ebola, to name a few. While these classiﬁers are in
various stages of development, very few have undergone extensive
testing or been further developed into a clinically available diagnostic test.
Added value of this study: We previously published gene expression signatures for distinguishing bacterial, viral, and noninfectious causes of respiratory illness using high dimensional ‘omicsbased techniques that had an overall accuracy of 87%. In this study,
we have implemented this signature onto a real-time PCR test and
demonstrated robust performance with AUROCs of 0•85–0•89. Additionally, the host response test showed promise in characterizing
more complex phenotypes, including bacterial-viral coinfection and
suspected but not microbiologically conﬁrmed infection. This study
is distinctive in its translation of our signatures to a standardized,
clinic-ready platform and its application to phenotypes that have
previously been excluded from testing.
Implications of all available evidence: The ability of a clinical
test to rapidly identify the presence or absence of an infection
and guide appropriate antibiotic use would improve individual patient care and mitigate the development of antibiotic resistance.
More generally, host response diagnostic signatures like the one
presented here represent a means by which diagnostics can enable
personalized medicine.

dent in vitro validation and typically excluded patients with complex phenotypes, such as the immunocompromised, coinfected,
chronically infected, or clinically ambiguous. Understanding performance in these heterogeneous populations is vital for the development of this new generation of tests.
We previously published a microarray-derived host gene expression classiﬁer that accurately distinguished bacterial, viral, and
noninfectious causes of acute respiratory illness [[17],[18]]. We
subsequently translated these signatures onto a real-time PCR test,
a reproducible and standardized diagnostic platform. Here, we validate this test’s ability to discriminate causes of acute respiratory
illness and explore the ability of the host response to characterize coinfected, chronically infected, and clinically equivocal cases
as compared to procalcitonin.
2. Materials and methods
2.1. Subject enrollment
Subjects with acute respiratory illness were prospectively enrolled in emergency departments at Duke University, Durham VA
Health Care System, Henry Ford Hospital, and University of North
Carolina as part of the CAPSOD (Community-Acquired Pneumonia
and Sepsis Outcome Diagnostics, ClinicalTrials.gov NCT00258869),
CAPSS (Community-Acquired Pneumonia and Sepsis Study), or
RADICAL (Rapid Diagnostics in Categorizing Acute Lung Infection)
studies. All studies were approved by the respective IRBs in accordance with institutional and federal regulations regarding the protection of human subjects. Written informed consent was obtained
from all subjects or legally authorized representatives.
2.2. Clinical adjudication and subject selection

1. Introduction
Diﬃculty in differentiating bacterial, viral, and noninfectious
etiologies of respiratory illness contributes to antibiotic overuse. In
the U.S., 73% of clinic visits and 61% of emergency department visits for suspected respiratory tract infection led to a prescription for
antibiotics, despite most having a viral etiology [[1],[2]]. Driven by
excess antibiotic use, antibiotic resistance is emerging at an alarming rate, outpacing novel antibiotic development and contributing
to rising healthcare costs [[3],[4]]. Diagnostic tests that discriminate these etiologies of illness could individualize care and mitigate inappropriate antibiotic use. However, traditional pathogenbased diagnostics have limited sensitivity, long time-to-result (as
with culture), require a priori suspicion of the pathogen (as with
molecular tests), and cannot differentiate infection from colonization.
Measuring the host response offers an alternative diagnostic
strategy. Procalcitonin, preferentially rising in bacterial infections,
has demonstrated clinical utility in safely decreasing antibiotic use,
though that ﬁnding was not reproduced in a recent, large, U.S.based study [[5],[6]]. With respect to its ability to distinguish bacterial and viral etiologies, procalcitonin has shown only modest
performance [7–9]. Biomarker panels that combine multiple analytes may impart greater sensitivity and speciﬁcity. Several studies have successfully deﬁned signatures that discriminate bacterial
and viral infection using high-dimensional ‘omics-based techniques
[10–16]. However, most signatures have not undergone indepen∗
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All subjects enrolled in CAPSOD, CAPSS, and RADICAL underwent clinical adjudication. This adjudication served as the reference standard for the study. Adjudications were conducted by
emergency medicine, hospital medicine, pulmonary medicine, or
infectious disease physicians after enrollment but prior to gene expression or procalcitonin measurements, as previously described
[[17],[19]]. Information supporting adjudication included history,
physical examination, clinical laboratory testing, and radiography.
Supplemental viral PCR testing was performed for all subjects using the ResPlex 2•0 viral PCR multiplex assay (Qiagen), xTAG RVP
FAST 2 (Luminex), or NxTAG Respiratory Pathogen Panel (Luminex).
Subjects were retrospectively selected for inclusion from the
larger pool of study subjects if they fell into one of several adjudicated categories. A “conﬁrmed” bacterial or viral infection required
the subject to have a compatible clinical syndrome and identiﬁed
pathogen. In the absence of supporting microbiological evidence,
adjudicators could still make a classiﬁcation of “suspected bacterial” or “suspected viral” infection if the clinical presentation was
consistent with this etiology. Adjudicators could identify multiple
infectious etiologies within one subject if multiple pathogens were
identiﬁed or if the clinical presentation was consistent with coinfection. Adjudication of noninfectious illness was made only when
microbiological testing was negative and an alternative, noninfectious diagnosis was established. Additional details regarding the
clinical adjudication and subject selection processes are available
in the Supplemental Methods section.
2.3. Host gene expression measurement
Peripheral whole blood was collected from each subject at enrollment. Total RNA was extracted using PAXgene Blood miRNA
kit (Qiagen). RNA quantity and quality were assessed by NanoDrop Spectrophotometer (Thermo Fisher Scientiﬁc) and Aligent
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2100 Bioanalyzer with RNA 6000 Nano kit, respectively. A cDNA
library was generated from total RNA using SuperScript VILO MasterMix (Thermo Fisher Scientiﬁc). Semi-quantitative, real-time PCR
was performed on custom TaqMan Low Density Arrays (TLDA)
[[20],[21]]. TLDA cards were customized to quantify 87 RNA transcripts (Table S1). Targets were selected from prior microarraybased studies in an iterative process, substituting poorly performing assays with different probes for the same transcript or with
other transcripts that were highly correlated with the original
[[17],[18]]. Additional details can be found in the Supplementary
Methods.

455

Procalcitonin testing was not obtained as part of clinical care
and was therefore available as an independent comparator without risking incorporation bias. Procalcitonin was measured using
serum or plasma, when available. Serum samples were measured
on the Roche Elecsys 2010 analyzer (Roche Diagnostics) or miniVIDAS immunoassay (bioMérieux). Plasma samples were measured
using B•R•A•H•M•S PCT sensitive KRYPTOR (Thermo Fisher Scientiﬁc). Measurements were treated equivalently regardless of platform. Values >0•25 μg/liter deﬁned bacterial infection and values
≤0•25 μg/liter deﬁned non-bacterial [24]. We compared procalcitonin and gene expression using McNemar’s test.

that would potentially undergo diagnostic testing. Use of this control population imparts greater speciﬁcity to the RT-PCR test. Demographically, the cohort was heterogeneous and encompassed a
racially diverse group across a wide age range (Table S2). Groups
were well-balanced with respect to gender and race, though the
viral cohort was younger (mean 42 years vs. 54 for bacterial and
58 for noninfectious) and less ill, as inferred by the rate of hospitalization (30%, 96%, and 86%, respectively). Table S3 presents the
bacterial, viral, and noninfectious illness etiologies.
The gene expression signature was ﬁrst identiﬁed in microarray data but validated using RT-PCR. Due to these technical differences, the models originally generated on microarray data cannot
be applied to RT-PCR data. Instead, retraining classiﬁer parameters
is required. Therefore, RT-PCR gene expression data from these 151
subjects was used to calibrate the classiﬁers (Table S1). Although
87 gene targets were included in the RT-PCR test, not all were selected and utilized by the model. Speciﬁcally, the LASSO methodology performed regularization and nested cross-validation to select
model parameters with model weights presented in Table S1. Only
those with non-zero weights were considered informative and retained. This included a total of 41 transcripts: 34 for the bacterial
model, 15 for the viral model, and 8 for the non-infectious illness
model. Some transcripts were utilized for more than one model
explaining why the total parameters for all three models exceeded
41.
Each classiﬁer is binary, and class membership is determined
by the highest of the three probabilities (bacterial, viral, or noninfectious). Using this methodology, leave-one-out cross-validation
revealed accurate discrimination between groups, with AUROC of
0•85 for bacterial, 0•89 for viral, and 0•88 for noninfectious illness (Fig. 2). When considering all three classes simultaneously,
the overall accuracy was 77% (116/151 concordant with adjudicated
phenotype). The host gene expression test identiﬁed bacterial infection with 75% (36/48) PPA and 92% (95/103) NPA (accuracy 88%).
This performance corresponds to a positive likelihood ratio of 3.68
for ruling in bacterial infection and a negative likelihood ratio of
0.27 for ruling out bacterial infection. Viral infection was identiﬁed
with 78% (42/54) PPA and 86% (83/97) NPA (accuracy 82%). With
the noninfectious classiﬁer, infection was correctly excluded in 78%
(38/49) of cases (84% accuracy).
Procalcitonin concentrations were obtained for 137 subjects
with samples available for testing. Procalcitonin correctly classiﬁed 114 of 137 (83%) as either bacterial or non-bacterial, compared
to 121 of 137 (88%) using the host response classiﬁers (p = 0•23)
(Fig. 2). Notably, the performance of the two tests differed based
on the classiﬁcation task. If excluding the non-infectious illness
group, accuracy was identical for the two tests in distinguishing
bacterial and viral cases (86% vs 86%, p = 1). However, the host
response classiﬁers correctly discriminated bacterial and noninfectious illness more frequently than procalcitonin, though the difference was not statistically signiﬁcant (86% vs 77%, p = 0•17). Procalcitonin is unable to discriminate viral from non-infectious etiologies. However, the host gene expression test correctly discriminated these two groups in 81% of cases.

3. Results

3.2. Performance in complex phenotypes

3.1. Bacterial, viral, and noninfectious classiﬁers

Having evaluated performance of the RT-PCR test in these subjects with a single, known etiology, we next evaluated a more clinically challenging series of phenotypes: coinfection and suspected
bacterial infection. Since the true state of these subjects was uncertain, we could not assess performance metrics. Instead, we used
the host gene expression RT-PCR test to characterize their underlying biological state (Fig. 1).
The validation described above utilized the highest predicted
probability as the test result. However, this does not allow for

2.4. Model calibration and validation
Due to technical differences between microarray measurements
and RT-PCR, we could not apply the microarray-based model to
this new data. We therefore trained a new model on RT-PCR data.
Speciﬁcally, RT-PCR gene expression data were average normalized against two reference transcripts with stable expression across
phenotypes (DECR1 and TRAP1). Data were generated in two distinct experiments. 19 technical replicates were utilized to assess
model robustness as well as identify potential batch differences,
which were corrected using an empirical Bayesian frameworks
model [22]. Correlation was high for these technical replicates
(R2 = 0•96) (Figure S1). Normalized, batch-corrected data from subjects with conﬁrmed bacterial, viral, or noninfectious illness were
used to ﬁt a logistic regression model. Scripts were written in R
using the Glmnet toolbox [23]. Speciﬁcally, we used Least Absolute Shrinkage and Selection Operator (LASSO) for regularization
and performed nested cross-validation to select parameters. This
resulted in three independent binary classiﬁers (bacterial versus
non-bacterial, viral versus non-viral, and noninfectious versus infectious), of which the largest probability determined class. Performance metrics included positive percent agreement (PPA), negative
percent agreement (NPA), and area under the receiver operating
characteristic curve (AUROC). The ﬁxed-weight model was then applied to subjects with coinfection and suspected bacterial infection.
To allow for coinfection, we deﬁned probability thresholds for the
bacterial and viral classiﬁers allowing us to identify four scenarios:
bacterial infection, viral infection, coinfection, and no infection.
2.5. Procalcitonin comparison

In the absence of a reliable gold standard to deﬁne infection
class, expert clinical adjudication served as the reference standard.
Thus, 151 subjects with adjudicated and microbiologically conﬁrmed phenotypes (48 bacterial, 54 viral, 49 noninfectious illness)
were identiﬁed to evaluate the RT-PCR test’s performance (Fig. 1).
Instead of healthy individuals, noninfectious illness was selected as
a control group since it represents a clinically relevant population
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Fig. 1. Experimental ﬂow. Coinfection cases included both superinfections (acute bacterial infection following an acute viral infection) and acute-on-chronic coinfections
(acute bacterial infection and chronic viral infection). Suspected bacterial cases were those without microbiological evidence but clinically adjudicated as bacterial. RT-PCR:
Real Time Polymerase Chain Reaction; AoC: acute-on-chronic.

Fig. 2. RT-PCR test performance compared to procalcitonin for microbiologically conﬁrmed, single etiology cases. Upper panels demonstrate AUROC curves for the
bacterial, viral, and noninfectious classiﬁers. Lower panels show the bacterial, viral, and non-infectious probabilities for each subject, organized by the clinically adjudicated
phenotype. Procalcitonin comparison is shown on the right side of the panel (values are in ng/mL). A maximum procalcitonin value of 10 ng/mL was used to improve data
visualization. RT-PCR: Real time polymerase chain reaction; AUROC: area under receiver operator characteristic; NI: non-infectious illness.

the identiﬁcation of coinfection. We therefore deﬁned probability thresholds for the bacterial classiﬁer and the viral classiﬁer.
This scheme allows for the identiﬁcation of bacterial infection, viral infection, both, or neither. This approach does not explicitly
use the noninfectious classiﬁer, but the noninfectious subjects are
still utilized in training the bacterial and viral classiﬁers to increase model speciﬁcity. A threshold of 0•45 was set for viral infection and 0•20 for bacterial infection, yielding ≥80% PPA for both
(Figure S2).
The coinfection cohort included 65 subjects (Table S4). Of
this group, 31 had positive testing for both bacterial and viral
pathogens. The remaining 34 had positive microbiology for one
pathogen and a clinical suspicion for the other pathogen class, or a

clinical syndrome consistent with bacterial-viral coinfection. Since
the timeline of coinfection can vary, we created subcategories. “Superinfection” (acute bacterial infection following recent acute viral
infection) included 53 subjects (19 microbiologically conﬁrmed and
34 suspected cases). Of the 19 subjects with microbiologically conﬁrmed superinfections, the RT-PCR test identiﬁed 18 as having a
bacterial infection (16 as bacterial alone, two as coinfection) with
one subject classiﬁed as noninfectious (Fig. 3A). Procalcitonin only
identiﬁed 68% (13/19) as bacterial (p = 0.13). In contrast, for the 34
subjects with clinically suspected superinfections without conﬁrmatory microbiology, the RT-PCR test identiﬁed an equal number
as bacterial or viral (12 each, 35%), six (18%) as coinfection, and
four (12%) as noninfectious (Fig. 3B). Procalcitonin was positive in
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Fig. 3. Signature application in cases of superinfection. “Superinfection” describes subjects with an acute bacterial infection temporally following an acute viral infection.
The red and black lines (left and right, respectively) depict the thresholds for bacterial infection and viral infection, respectively. The dashed lines divide the subjects into
their model-predicted classes based on thresholding: bacterial infection, viral infection, coinfection, and no infection. 3A, Model application in microbiologically conﬁrmed
superinfections (n = 19). 3B, Model application in clinically adjudicated superinfections without microbiological conﬁrmation. (For interpretation of the references to color in
this ﬁgure legend, the reader is referred to the web version of this article.)

Fig. 4. Signature application in cases of acute-on-chronic coinfections. “Acute-on-chronic” coinfection describes subjects with chronic viral infection and acute bacterial
infection. All subjects had microbiologically conﬁrmed acute bacterial infections. The red and black lines (left and right, respectively) show the thresholds for bacterial
infection and viral infection, respectively. The dashed lines divide the subjects into their model-predicted classes based on thresholding: bacterial infection, viral infection,
coinfection, and no infection. 4A, Model application in chronically infected subjects with detectable or unknown viral load (n = 8). 3B, Model application in chronically
infected subjects with a suppressed viral load (n = 4). (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this
article.)

only 13 subjects (53% vs 38%, p = 0•27, for identifying bacterial infection; Table S5).
The “acute-on-chronic” coinfection cohort included 12 subjects
with chronic viral infections (HIV, hepatitis B/C, or CMV) and superimposed acute bacterial infections, all of which were microbiologically conﬁrmed. Six subjects had detectable viral loads, two had
unknown viral loads, and four had suppressed viral loads. Those
with detectable or unknown viral loads had a mixed host response:
ﬁve (63%) were classiﬁed as bacterial, one (13%) as coinfection, one
(13%) as noninfectious, and one (13%) as viral (Fig. 4A). In contrast,
all four individuals with suppressed viral loads had a bacterial host
response (Fig. 4B). Procalcitonin aligned with the RT-PCR test for
each of the 11 subjects in this subcategory that had available procalcitonin resultsFig. 5.

We also applied the RT-PCR test to 39 subjects with a suspected
bacterial infection (Fig. 5). These were subjects who were clinically
adjudicated as having a bacterial infection on clinical grounds (e.g.
radiographic inﬁltrate, neutrophilic leukocytosis, hypoxia) but no
identiﬁed pathogen. Of these, the RT-PCR test identiﬁed 29 (74%) as
bacterial, three (8%) as coinfection, ﬁve (13%) as noninfectious, and
two (5%) as viral. Procalcitonin identiﬁed a bacterial infection in
64% of cases compared to 82% for host gene expression (p = 0•02).
4. Discussion
We previously published microarray-based host response signatures that successfully discriminated bacterial, viral, and noninfectious causes of respiratory illness with an overall accuracy of
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Fig. 5. Signature application in cases of suspected bacterial infections. “Suspected bacterial” describes subjects clinically adjudicated as bacterial infection but without
microbiological conﬁrmation (n = 39). The red and black lines (left and right, respectively) show the thresholds for bacterial infection and viral infection, respectively. The
dashed lines divide the subjects into their model-predicted classes based on thresholding: bacterial infection, viral infection, coinfection, and no infection. (For interpretation
of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)

87% [17]. Here, we translated those signatures to a RT-PCR platform and demonstrated robust performance when validated in an
independent cohort of microbiologically conﬁrmed bacterial, viral,
or noninfectious cases. With a targeted RT-PCR test, the bacterial,
viral, and noninfectious classiﬁers had overall accuracies of 88%,
82%, and 84%, respectively (AUROCs 0•85–0•89) compared to an
imperfect reference standard. The corresponding positive and negative likelihood ratios for bacterial vs. non-bacterial infection were
3.68 and 0.27, respectively. These values in and of themselves are
unlikely to rule in or rule out bacterial infection. However, when
used in conjunction with other clinical data, such a test would
be a valuable adjunct. Furthermore, the likelihood ratios could be
tuned by choosing different statistical cutoffs that incorporate the
clinical signiﬁcance of false positive and false negative errors. One
statistic that accomplishes this is the average weighted accuracy
[25]. The other validation described in this study was in cases of
bacterial-viral coinfection, successfully identifying a bacterial infection in nearly all microbiologically conﬁrmed cases even in the
presence of a concurrent viral illness. These encouraging results
suggest that such a host gene expression-based diagnostic test has
the potential to individualize treatment and mitigate inappropriate
antibiotic prescribing.
Other studies have also investigated gene expression-based
classiﬁers for diagnosing various infections. This growing body of
work includes classiﬁers for acute respiratory illness [[15],[16]],
sepsis [[26],[27]], and pediatric febrile illness [[14],[28],[29]], as
well as pathogen-speciﬁc classiﬁers for tuberculosis [[30],[31]],
Lyme disease [32], and Ebola [33]. In contrast to most of these
studies, which used microarray or sequencing for signature discovery and validation, we validated signature performance using a
standardized RT-PCR platform. This is particularly notable because
RT-PCR can be readily translated to rapid, clinically relevant platforms [[34],[35]]. Furthermore, our study is distinctive in its exploration of complex phenotypes, including coinfection and indeterminate infection. The translation of a bacterial/viral host response
signature to a clinically-relevant platform, as demonstrated in this
study, has signiﬁcance beyond this application. The advances presented here illustrate how this approach can be applied to a multitude of infectious diseases (e.g., tuberculosis, sepsis, undifferen-

tiated fever, rickettsial disease) and non-infectious diseases (e.g.,
coronary artery disease, oncology, rheumatoid arthritis, systemic
lupus erythematosus).
The exact incidence of bacterial-viral coinfection in respiratory
tract infection is unclear, with estimates ranging from 7% to 66%
[36–38]. As a result, concerns about coinfection drive a signiﬁcant
amount of inappropriate antibiotic use even when clinical testing identiﬁes a viral etiology [39]. Understanding signature performance in this population is a critical step toward the adoption
of gene expression-based testing. Most gene expression-focused
studies either exclude this phenotype, have a very small sample
size, or do not explore the multiple different categories of coinfection. Therefore, we applied our host response test, which offers
independent probabilities of bacterial and viral infection, to multiple types of coinfection. Among this group, the bacterial host response was most often the dominant signature. This may be due
to the temporal nature of the infections. With common superinfection scenarios (viral infections followed by a superimposed bacterial infection) and acute-on-chronic infections (chronic viral infection with an acute bacterial infection), the bacterial infection is
the more proximate stress on the immune system. Fortunately, this
is clinically desirable: the ability to successfully identify a bacterial
or coinfection signature would promote the appropriate use of antibacterials in this population.
Within the acute-on-chronic subgroup, a notable pattern
emerged based on the level of viremia. The four subjects with suppressed viral loads all had a strong bacterial host response, while
the eight subjects with detectable viral loads had mixed results
with some subjects revealing a prominent viral host response. This
division is supported by earlier work that explored gene expression in active and suppressed HIV [40–42]. One study performed
gene expression analysis on individuals before and after initiation
of anti-retrovirals and identiﬁed several thousand genes with differential expression. The genes with the largest fold change in expression included several interferon-related genes, such as IFI27,
which is a component of the RT-PCR test [40]. Although this subgroup is small within our study, these results underscore the importance of evaluating future host response classiﬁers in subjects
with chronic infections like HIV.
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Individuals with suspected but unconﬁrmed respiratory infection represent a challenge from both an antibiotic stewardship
and a diagnostic development standpoint. This situation is very
common; the Etiology of Pneumonia in the Community (EPIC)
study employed extensive microbiological testing in adults hospitalized with community acquired pneumonia and did not identify
a pathogen in 62% of cases [43]. With current diagnostics, it is impossible to know what proportion of this group can be attributed
to poor pathogen detection sensitivity versus an underlying noninfectious process. Here, we applied the signatures to 39 subjects
with etiology-negative suspected bacterial cases and found that
82% had a bacterial host response with the rest distributed across
the other diagnostic possibilities. While it is diﬃcult to gauge the
accuracy of the host response signature in any individual subject,
the summary statistics provide insights for these indeterminate patients in ways that current pathogen-based methods cannot.
In comparison to procalcitonin, the RT-PCR test offered similar
performance in distinguishing bacterial versus non-bacterial infections (accuracy 88% vs. 83%, p = 0•23). Prior studies have shown the
superiority of multi-analyte panels compared to procalcitonin including this signature measured using microarrays; we observed a
similar trend though our study was likely underpowered to achieve
statistical signiﬁcance [[16],[17],[44]]. The difference between host
gene expression and procalcitonin was most pronounced in two
scenarios. The ﬁrst was based on the inability of procalcitonin
to distinguish viral from non-infectious illness. In contrast, the
host gene expression test correctly classiﬁed 81% of these cases.
The second major improvement over procalcitonin was in cases of
bacterial-viral coinfection. This could be explained by prior experiments showing that in human cell lines cultured with both bacterial and viral pathogens, viral-induced interferon signaling dominated, resulting in procalcitonin inhibition [45]. These ﬁndings represents an important yet underappreciated limitation of procalcitonin for which the host gene expression test signiﬁcantly advances clinical diagnostics. For example, a recent meta-analysis
evaluating the ability of procalcitonin to distinguish viral from bacterial pneumonia revealed only 55% sensitivity and 76% speciﬁcity
using established thresholds [9]. It is also important to highlight
that procalcitonin addresses only one diagnostic question: bacterial or non-bacterial infection. It does not discriminate viral infection from non-infectious illness, nor can it reliably identify bacterial/viral co-infection. In contrast, our approach with independent bacterial and viral classiﬁers allows four possible diagnoses:
bacterial infection, viral infection, coinfection, or no infection. Despite similar performance for bacterial vs. non-bacterial infection,
the host gene expression test accurately discriminated viral from
non-infectious etiologies and was signiﬁcantly better at identifying bacterial/viral co-infection compared to procalcitonin. Focusing
exclusively on bacterial vs. non-bacterial classiﬁcation oversimpliﬁes clinical practice as highlighted by the inability of procalcitonin
to impact antibiotic utilization in a large, U.S.-based randomized
clinical trial . The more comprehensive diagnostic information offered by host gene expression could therefore provide signiﬁcant
improvements over current methods to identify the cause of acute
respiratory illness.
A host response approach should also be differentiated from a
pathogen-detection strategy. A combination of the two represents
an ideal strategy but is often impractical due to cost and time considerations. Pathogen-detection tests encompass many technologies including culture, rapid antigen detection tests, and nucleic
acid ampliﬁcation tests. Advantages and disadvantages of these approaches have been reviewed elsewhere [46]. However, one of the
limitations common to all is the inability to distinguish infection
from colonization (asymptomatic shedding), which has been observed for all the pathogens included on these various test panels [[47],[48]]. A negative result does not exclude the presence
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of that pathogen (due to sampling bias or poor test sensitivity)
nor does it exclude the presence of other pathogens. This concern
also extends to situations where a pathogen detection test is positive. Speciﬁcally, a positive result (even if due to infection and not
colonization) does not exclude the presence of other, undetected
pathogens. All of these limitations are addressed by using a host
gene expression approach that independently provides information
about both bacterial and viral infection. The host gene expression
test described here identiﬁes the presence of a bacterial or viral
infection when positive and also excludes such an infection when
negative.
Perhaps the most signiﬁcant limitation of the study is the lack
of a gold standard to diagnose bacterial or viral infection. Consequently, discordant classiﬁcations could represent errors in adjudication or in the test. The validation presented here was performed
at two levels. The ﬁrst included an independent validation of the
signature (the speciﬁc combination of gene expression targets) in
subjects with bacterial, viral, or non-infectious illness. The second
validation was of the model (logistic regression model assigning
weights to each mRNA in the signature) in a cohort of subjects
with complex phenotypes. However, we did not validate the model
in an independent cohort of subjects with only a bacterial, viral, or
non-infectious etiology. Doing so would further improve external
validity. Some categories of coinfection, particularly the chronic viral infection group, were too small to draw deﬁnitive conclusions.
Relatedly, we did not have the opportunity to explore rarer types
of coinfection, including acute viral/chronic bacterial infections and
coinfections occurring at distinct anatomic sites (e.g. concurrent
respiratory viral infection and urinary tract infection). While the
cohorts included individuals as young as 14 years, these results
should be validated in younger children. However, the gene expression signatures themselves were validated in silico in a large cohort
of pediatric cases [17]. Finally, it is important to acknowledge that
the RT-PCR test can only determine pathogen class. In most patients, this is adequate for guiding antibiotic selection. However, in
sicker, hospitalized patients, knowing the pathogen type and susceptibility proﬁle can be important for clinical care. Therefore, host
response-based testing should be viewed as part of a comprehensive diagnostic strategy, rather than a replacement for conventional
pathogen-based testing.
Looking forward, the next challenge will be shortening the
turnaround time of the RT-PCR test. The platform described in
this study requires several hours of hands-on processing time,
which is acceptable for most inpatient settings. However, a test
that is simpler to perform and provides more rapid results could
be transformative in primary care or the emergency department.
Further translation of this host response signature is currently underway, with an estimated time-to-result of approximately 45 min
[[34],[35]].
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